Knuff & Co LLC Has $833,000 Stake in Moderna, Inc. (NASDAQ:MRNA)

Knuff & Co LLC trimmed its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 59.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,380 shares of the company’s stock after selling 12,417 shares during the period. Knuff & Co LLC’s holdings in Moderna were worth $833,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Arlington Trust Co LLC grew its stake in Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares in the last quarter. GPS Wealth Strategies Group LLC boosted its stake in shares of Moderna by 54.1% in the 3rd quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock valued at $53,000 after purchasing an additional 180 shares in the last quarter. Archer Investment Corp boosted its stake in shares of Moderna by 71.2% in the 3rd quarter. Archer Investment Corp now owns 534 shares of the company’s stock valued at $55,000 after purchasing an additional 222 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Moderna by 44.9% in the 3rd quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock valued at $58,000 after purchasing an additional 175 shares in the last quarter. Finally, Hexagon Capital Partners LLC boosted its stake in shares of Moderna by 182.4% in the 4th quarter. Hexagon Capital Partners LLC now owns 610 shares of the company’s stock valued at $61,000 after purchasing an additional 394 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Down 0.5 %

NASDAQ MRNA traded down $0.59 during mid-day trading on Friday, hitting $125.00. The company’s stock had a trading volume of 4,513,133 shares, compared to its average volume of 3,445,723. The company’s 50 day simple moving average is $105.05 and its 200 day simple moving average is $94.42. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $142.79. The company has a current ratio of 4.03, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $47.86 billion, a price-to-earnings ratio of -7.98 and a beta of 1.57.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. During the same quarter last year, the firm posted $0.19 EPS. Moderna’s revenue was down 91.0% compared to the same quarter last year. Analysts anticipate that Moderna, Inc. will post -7.47 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price target on shares of Moderna in a research note on Tuesday, April 9th. HSBC reiterated a “reduce” rating and issued a $86.00 price objective (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Thursday. Royal Bank of Canada raised their price objective on shares of Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Friday. Finally, Oppenheimer raised their price objective on shares of Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a report on Friday. Two analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $129.55.

Insider Activity at Moderna

In other news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the sale, the president now owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the transaction, the president now directly owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Shannon Thyme Klinger sold 670 shares of Moderna stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $63,361.90. Following the sale, the insider now owns 8,557 shares in the company, valued at $809,235.49. The disclosure for this sale can be found here. In the last 90 days, insiders sold 139,954 shares of company stock valued at $14,822,576. 15.70% of the stock is owned by company insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.